| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.61B | -3.0% | -7.1% |
| R&D Expense | $19.0M | +18.8% | -5.0% |
| SG&A Expense | $621.5M | -1.3% | -3.4% |
| Operating Income | -$16.64B | -7698.1% | — |
| Pre-tax Income | -$16.94B | -4219.1% | -9363.9% |
| Income Tax | -$4.16B | -4772.2% | — |
| Net Income | -$12.78B |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.43B | +3.7% | +290.6% |
| Short-term Investments | $1.48B | -25.4% | +2763.0% |
| Accounts Receivable | $1.13B | -2.7% | +2.5% |
| Inventory | $416.1M | +10.9% | -5.8% |
| Current Assets | $6.03B | -12.8% | +20.6% |
| Total Assets |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $325.9M | — | — |
| Capital Expenditures | $807.6M | — | — |
| Investing Cash Flow | -$1.65B | — | — |
| Financing Cash Flow | -$562.9M | — | — |
| Free Cash Flow | -$481.7M | — | — |
| -8912.8% |
| EPS (Basic) | -$44.37 | -4085.8% | -8432.7% |
| EPS (Diluted) | -$44.37 | -4085.8% | -8432.7% |
| $45.27B |
| -24.4% |
| -21.3% |
| Current Liabilities | $9.96B | +75.6% | +33.2% |
| Long-term Debt | $21.79B | -14.2% | — |
| Total Liabilities | $38.26B | -4.6% | +0.6% |
| Stockholders' Equity | $6.95B | -64.8% | -64.2% |